Tazarotene

also known as Tazorac · IDP-123 · DFD-03 · Taz · AGN 190168 · Arazlo · Avage · Fabior · +5 more

Developed for: acne · psoriasis · hand-foot syndrome · acne keloid · actinic keratosis · exanthem · hyperpigmentation of the skin · idiopathic pulmonary fibrosis
+7 more
· lentigo maligna melanoma · neoplastic syndrome · primary cutaneous T-cell lymphoma · skin carcinoma · skin disorder · skin disorder caused by infection · adult acne
Investigated by: GlaxoSmithKline · Stiefel, a GSK Company · Bausch Health Americas, Inc. · Dr. Reddy's Laboratories Limited · Allergan · Assiut University
+31 more
· Bayer · Dow Pharmaceutical Sciences · Icahn School of Medicine at Mount Sinai · National Cancer Institute (NCI) · Ortho Dermatologics · UCSF Benioff Children's Hospital Oakland · University of Utah · All India Institute of Medical Sciences, Bhubaneswar · Almirall, S.A. · Austin Institute for Clinical Research · Columbia University · Dana-Farber Cancer Institute · Dermatology Consulting Services, PLLC · Dr. Emmy Graber · Fougera Pharmaceuticals Inc. · G & W Laboratories Inc. · GRI Bio Operations, Inc. · Jefferson Medical College of Thomas Jefferson University · Jinnah Postgraduate Medical Centre · KGL, Inc. · McGill University · Milton S. Hershey Medical Center · NYU Langone Health · Northwestern University · Post Graduate Institute of Medical Education and Research, Chandigarh · State University of New York - Downstate Medical Center · Stewart, Roger H., M.D., P.A. · Sun Pharmaceutical Industries, Inc. · Unilever R&D · University of Michigan · Zagazig University

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed acne 1 milestone
Filed	US (FDA)	—	acne	2011-08-03	“it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam” gsk.com ↗
Approved Indication not stated 2 milestones
Label expansions (2)	US (FDA)	TAZORAC	—	2001-10-11 – 2002-09-30	fda.gov ↗
Approved	US (FDA)	TAZORAC	—	1997-06-13	fda.gov ↗

Trials 44

today

US approved 1997

NCT06331624 · Ph 2 NCT05872256 · Ph 4 NCT05555797 · Ph 4 NCT05608499 · Ph 3 NCT06015152 · not/applicable NCT05314127 · Ph 2 NCT05203315 · Ph 3 NCT05704114 · Ph 4 NCT04720105 · Ph 4 NCT04071756 · Ph 2 NCT03599193 · Ph 2 NCT03263624 · Ph 4 NCT03341910 · Ph 2 NCT03290027 · Ph 3 NCT03168334 · Ph 3 NCT03292640 · Ph 3 NCT03168321 · Ph 3 NCT03170596 · not/applicable NCT02886702 · Ph 3 NCT02721173 · Ph 4 NCT02938494 · Ph 2 NCT02462083 · Ph 3 NCT02411955 · Ph 1 NCT02160665 · Ph 3 NCT02235480 · Ph 2 NCT02045277 · Ph 2 NCT01119651 · Ph 1 NCT01115322 · Ph 1 NCT01114841 · Ph 1 NCT01112787 · Ph 1 NCT01053000 · not/applicable NCT01094717 · not/applicable NCT01017146 · Ph 3 NCT01019603 · Ph 1 NCT01017120 · Ph 3 NCT00779896 · Ph 1/2 NCT00713609 · Ph 2 NCT00667589 · Ph 2 NCT00440024 · not/applicable NCT00648986 · Ph 4 NCT00707174 · not/applicable NCT00783965 · Ph 2 NCT00489086 · Ph 2 NCT00145106 · Ph 4

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT02411955	Jun 2014 → Jan 2015	acne	Sun Pharmaceutical Industries, Inc.	Completed	No outcome recorded
Phase 1	NCT01119651	Jun 2010	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 1	NCT01115322	Apr 2010	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 1	NCT01114841	Mar → Jun 2010	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 1	NCT01112787	Mar → Apr 2010	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 1	NCT01019603	Oct → Dec 2009	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00779896	Oct 2008 → Dec 2011	primary cutaneous T-cell lymphoma	McGill University	Unknown	No outcome recorded
Phase 212 trials
Phase 2	NCT06331624	Apr 2024 → Sep 2025	idiopathic pulmonary fibrosis	GRI Bio Operations, Inc.	Completed	No outcome recorded
Phase 2	NCT05314127	Apr → Oct 2022	skin disorder caused by infection	Zagazig University	Unknown	No outcome recorded
Phase 2	NCT04071756	Dec 2019 → Jun 2021	cancer, hand-foot syndrome	Dana-Farber Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03599193	Oct 2017 → Apr 2018	acne	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 2	NCT03341910	Aug 2017 → May 2018	acne	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 2	NCT02938494	Nov 2015 → Jul 2016	acne	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 2	NCT02235480	Feb → May 2014	psoriasis	Almirall, S.A.	Completed	No outcome recorded
Phase 2	NCT02045277	Feb → Nov 2014	psoriasis	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 2	NCT00713609	Jun 2008 → Mar 2009	acne	Stiefel, a GSK Company	Completed	Mixed
Phase 2	NCT00667589	Jun 2008 → Dec 2010	exanthem, hand-foot syndrome	Northwestern University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00783965	Jul 2004 → Jun 2012	skin carcinoma	UCSF Benioff Children's Hospital Oakland	Completed	No outcome recorded
Phase 2	NCT00489086	Jul 2004 → Jun 2012	neoplastic syndrome	UCSF Benioff Children's Hospital Oakland	Completed	No outcome recorded

Phase 311 trials · 2 met primary · 1 missed
Phase 3	NCT05608499	Oct 2022 → Apr 2024	acne keloid	Icahn School of Medicine at Mount Sinai	Terminated	No outcome recorded
Phase 3	NCT05203315	Jan 2022 → Oct 2023	psoriasis	Austin Institute for Clinical Research	Completed	No outcome recorded
Phase 3	NCT03290027	Jul 2017 → Apr 2018	acne	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 3	NCT03168334	Jul 2017 → Jul 2018	acne	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 3	NCT03292640	Jul 2017 → May 2018	acne	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 3	NCT03168321	Jun 2017 → Jun 2018	acne	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 3	NCT02886702	Sep 2016 → Aug 2017	psoriasis	Fougera Pharmaceuticals Inc.	Completed	Missed primary
Phase 3	NCT02462083	Aug 2015 → Jan 2017	psoriasis	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 3	NCT02160665	May 2014 → May 2016	psoriasis	G & W Laboratories Inc.	Completed	No outcome recorded
Phase 3	NCT01017120	Oct 2009 → Nov 2010	acne	Stiefel, a GSK Company	Completed	Met primary
Phase 3	NCT01017146	Oct 2009 → Nov 2010	acne	Stiefel, a GSK Company	Completed	Met primary

Phase 48 trials · 1 met primary
Phase 4	NCT05872256	Jun → Nov 2023	psoriasis	Dermatology Consulting Services, PLLC	Completed	No outcome recorded
Phase 4	NCT05555797	Oct 2022 → Sep 2023	psoriasis	Assiut University	Unknown	No outcome recorded
Phase 4	NCT05704114	Feb 2021 → Feb 2022	acne, hyperpigmentation of the skin	Dr. Emmy Graber	Completed	No outcome recorded
Phase 4	NCT04720105	Nov 2020 → Mar 2022	psoriasis	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT03263624	Oct 2017 → Oct 2018	psoriasis	Assiut University	Unknown	No outcome recorded
Phase 4	NCT02721173	Apr → Dec 2016	acne	All India Institute of Medical Sciences, Bhubaneswar	Completed	Met primary
Phase 4	NCT00648986	Aug 2005 → Dec 2006	—	Columbia University	Completed	No outcome recorded
Phase 4	NCT00145106	Mar → Aug 2002	acne	KGL, Inc.	Completed	No outcome recorded
Phase not applicable6 trials · 1 missed
—	NCT06015152	Aug → Dec 2022	psoriasis	Jinnah Postgraduate Medical Centre	Completed	No outcome recorded
—	NCT03170596	Jun 2017 → Feb 2018	—	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
—	NCT01053000	Jan → Nov 2010	actinic keratosis	Stewart, Roger H., M.D., P.A.	Completed	No outcome recorded
—	NCT01094717	Jan 2010 → Sep 2011	psoriasis	University of Utah	Terminated	No outcome recorded Stop: Business
—	NCT00440024	Feb 2007 → Nov 2009	skin disorder	University of Michigan	Completed	No outcome recorded
—	NCT00707174	Mar 2005 → Mar 2013	lentigo maligna melanoma	University of Utah	Completed	Missed primary
Comparator or background therapy15 trials
Phase 1	NCT02849873 Comparator	Jun → Dec 2016	acne	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 1	NCT03058744 Comparator	Apr 2015 → Dec 2016	psoriasis	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 1	NCT02218034 Comparator	Aug 2014 → Mar 2015	acne	Allergan	Completed	No outcome recorded
Phase 2	NCT02785159 Comparator	Feb → Nov 2016	psoriasis	Bausch Health Americas, Inc.	Completed	No outcome recorded
Phase 2	NCT02525822 Comparator	Sep 2015 → Jun 2016	acne	Valeant Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT01616654 Comparator	Jun 2012 → Jul 2013	acne	Galderma R&D	Completed	Mixed
Phase 2/3	NCT05573425 Comparator	Aug 2020 → Feb 2021	adult acne	Jinnah Postgraduate Medical Centre	Completed	No outcome recorded
Phase 3	NCT02886715 Comparator	Sep 2016 → May 2017	acne	Fougera Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 3	NCT02267746 Comparator	Jun → Sep 2014	acne	Actavis Inc.	Completed	No outcome recorded
Phase 3	NCT02160678 Comparator	May 2014 → Jul 2015	acne	G & W Laboratories Inc.	Completed	No outcome recorded
Phase 4	NCT06042647 Comparator	Jul → Nov 2023	psoriasis	Dermatology Consulting Services, PLLC	Completed	No outcome recorded
Phase 4	NCT01016977 Comparator	Oct 2009 → Apr 2010	acne	Stiefel, a GSK Company	Completed	No outcome recorded
Phase 4	NCT00834210 Comparator	Dec 2008 → Sep 2009	acne	Allergan	Completed	No outcome recorded
Phase 4	NCT00829049 Comparator	Oct 2007 → Oct 2008	acne	Allergan	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00469755 Comparator	Feb → Sep 2006	acne	Galderma R&D	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 5

Date	Issuer	Release
2026-09-08	GRI Bio Operations, Inc.	Results GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621’s Mechanism of Action in IPF Across Nine Mechanistic Pillars gribio.com ↗ GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced new translational biomarker data from the Phase 2a GRI-0621-IPF-02 study evaluating GRI-0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis (“IPF”).
2026-06-18	GRI Bio Operations, Inc.	Regulatory GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis gribio.com ↗
2022-09-20	Cosette Pharmaceuticals, Inc.	Regulatory Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity cosettepharma.com ↗
2012-05-11	GlaxoSmithKline	Regulatory Stiefel receives US FDA approval of Fabior™ Foam, 0.1% gsk.com ↗ Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
2011-08-03	GlaxoSmithKline	Regulatory Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam gsk.com ↗ it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), for tazarotene foam

All press releases naming this drug 26 releases

Date	Issuer	Release
2026-09-08	GRI Bio Operations, Inc.	GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621’s Mechanism of Action in IPF Across Nine Mechanistic Pillars gribio.com ↗
2026-08-24	GRI Bio Operations, Inc.	GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 gribio.com ↗
2026-06-18	GRI Bio Operations, Inc.	GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis gribio.com ↗
2026-05-14	GRI Bio Operations, Inc.	GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline gribio.com ↗
2026-01-08	GRI Bio Operations, Inc.	GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 gribio.com ↗
2025-07-01	GRI Bio Operations, Inc.	GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2025-06-26	GRI Bio Operations, Inc.	GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2025-05-22	GRI Bio Operations, Inc.	GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results gribio.com ↗
2025-05-15	GRI Bio Operations, Inc.	GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 gribio.com ↗
2025-05-08	GRI Bio Operations, Inc.	GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2025-05-07	GRI Bio Operations, Inc.	GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2025-04-01	GRI Bio Operations, Inc.	GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2025-03-17	GRI Bio Operations, Inc.	GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2024-11-21	GRI Bio Operations, Inc.	GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
2024-11-14	GRI Bio Operations, Inc.	GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis gribio.com ↗
2024-10-16	GRI Bio Operations, Inc.	GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
2024-09-26	GRI Bio Operations, Inc.	GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia gribio.com ↗
2024-07-02	GRI Bio Operations, Inc.	GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine gribio.com ↗
2024-05-20	GRI Bio Operations, Inc.	GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) gribio.com ↗
2024-03-04	GRI Bio Operations, Inc.	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom gribio.com ↗
2023-12-05	GRI Bio Operations, Inc.	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2023-11-27	GRI Bio Operations, Inc.	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) gribio.com ↗
2023-09-01	GRI Bio Operations, Inc.	IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution? gribio.com ↗
2022-09-20	Cosette Pharmaceuticals, Inc.	Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity cosettepharma.com ↗
2012-05-11	GlaxoSmithKline	Stiefel receives US FDA approval of Fabior™ Foam, 0.1% gsk.com ↗
2011-08-03	GlaxoSmithKline	Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam gsk.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 61 sources stand behind the page.

Field	Value	Cited text
Known as	tazarotene	“Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis,...” NCT05203315 ↗ 53 “IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.” NCT02462083 ↗ “Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris” NCT02938494 ↗ “Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.” NCT02525822 ↗ “halobetasol propionate 0.01%/tazarotene 0.045% lotion” NCT04720105 ↗ “halobetasol propionate \[HP\], tazarotene \[Taz\]” NCT02045277 ↗ “halobetasol propionate and tazarotene” NCT05608499 ↗ “Tazorac (Tazarotene) Cream, 0.05%” NCT02785159 ↗ “DFD-03 (Tazarotene) Lotion, 0.1%” NCT03341910 ↗ “DFD-03 (0.1% tazarotene) Lotion” NCT03290027 ↗ “Tazarotene 0.045% Lotion” NCT03168321 ↗ Show 43 more sources
Known as	AGN 190168	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	Arazlo	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	Avage	“Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis...” PMID 20213916 ↗ Feb 2009
Known as	DFD-03	“DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off” NCT03599193 ↗ 1 “DFD-03 (Tazarotene) Lotion, 0.1%” NCT03341910 ↗
Known as	Fabior	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	GRI-0621	“Tazarotene (GRI-0621)” NCT06331624 ↗
Known as	IDP-123	“Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris” NCT02938494 ↗ 2 NCT02849873 ↗ NCT02525822 ↗
Known as	Taz	“Duobrii® lotion (halobetasol propionate \[HP\] and tazarotene \[Taz\] 0.01%/0.045%) is currently on the market for the treatment of moderate to severe stable plaque psoriasis,...” NCT05203315 ↗ 1 “Tazarotene (TAZ) is a topical retinoid with retinoic acid receptor β / γ receptor specificity.” NCT05555797 ↗
Known as	Tazarotene component of duobrii	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	Tazarotene component of idp-118	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	Tazaroteno	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Known as	Tazorac	“Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis...” PMID 20213916 ↗ Feb 2009 11 “Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours” NCT03599193 ↗ “TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.” NCT02886702 ↗ “Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)” NCT02160665 ↗ “Tazorac® (Tazarotene) Cream, 0.1%” NCT03341910 ↗ NCT02160665 ↗ NCT02849873 ↗ NCT00648986 ↗ NCT00440024 ↗ NCT01053000 ↗ NCT03058744 ↗ Show 1 more source
Known as	Zorac	ChEMBL registry synonym — accepted as the source's own label CHEMBL1657 ↗
Modality	Small molecule	“a receptor-selective synthetic retinoid” NCT00648986 ↗
Route	Topical	“topical tazarotene” NCT00145106 ↗